Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.

Rossing P, Lindhardt M, Tikkanen CK, Menon J, Cattin J, Hunt B, Malkin SJP, Chubb B, Damgaard T, Borg R

Cardiovascular diabetology20 Dec 2025Cited by 2 (Europe PMC)

PMID41422027PMCIDPMC12862915DOI10.1186/s12933-025-03002-1PepBankPUB-41422027

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01Computer modelIn silicoOther
In a model of adults with type 2 diabetes and chronic kidney disease in Denmark, semaglutide was projected to add 0.60 QALYs versus placebo.
In plain wordsIn a computer model for diabetes with kidney disease, semaglutide was projected to add healthy life years versus placebo.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy, full population
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
QALY gain
0.6 QALYs
full population
Source sentences
Summary
Treatment with semaglutide was projected to improve long-term quality-adjusted life expectancy by 0.60 quality-adjusted life years (QALYs) compared with placebo in the full population and by 0.44 and 0.62 QALYs in subgroups receiving/not receiving SGLT-2 inhibitors at baseline, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202701
02Computer modelIn silicoOther
In a model of adults with type 2 diabetes and chronic kidney disease in Denmark receiving SGLT-2 inhibitors, semaglutide was projected to add 0.44 QALYs versus placebo.
In plain wordsIn a computer model for diabetes with kidney disease and SGLT-2 drugs, semaglutide was projected to add healthy life years versus placebo.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy, patients on SGLT-2 inhibitors
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
QALY gain
0.44 QALYs
SGLT-2 inhibitors at baseline
Source sentences
Summary
Treatment with semaglutide was projected to improve long-term quality-adjusted life expectancy by 0.60 quality-adjusted life years (QALYs) compared with placebo in the full population and by 0.44 and 0.62 QALYs in subgroups receiving/not receiving SGLT-2 inhibitors at baseline, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202702
03Computer modelIn silicoOther
In a model of adults with type 2 diabetes and chronic kidney disease in Denmark not receiving SGLT-2 inhibitors, semaglutide was projected to add 0.62 QALYs versus placebo.
In plain wordsIn a computer model for diabetes with kidney disease and no SGLT-2 drugs, semaglutide was projected to add healthy life years versus placebo.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy, patients not on SGLT-2 inhibitors
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
QALY gain
0.62 QALYs
no SGLT-2 inhibitors at baseline
Source sentences
Summary
Treatment with semaglutide was projected to improve long-term quality-adjusted life expectancy by 0.60 quality-adjusted life years (QALYs) compared with placebo in the full population and by 0.44 and 0.62 QALYs in subgroups receiving/not receiving SGLT-2 inhibitors at baseline, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202703
04Computer modelIn silicoEfficacy outcome
In a model of adults with type 2 diabetes and chronic kidney disease, the projected QALY gain was driven mainly by lower kidney failure incidence with semaglutide versus placebo.
In plain wordsIn a computer model of adults with diabetes and kidney disease, semaglutide led to fewer cases of kidney failure than placebo.
Peptide
Semaglutide
Outcome
DecreaseKidney failure incidence
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Differences were predominantly driven by a reduced incidence of kidney failure with semaglutide versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202704
05Computer modelIn silicoOther
In a model of adults with type 2 diabetes and chronic kidney disease in Denmark, semaglutide was projected to save DKK 6,068 per person versus placebo.
In plain wordsIn a computer model of Danish adults with diabetes and kidney disease, semaglutide was projected to cost less over a lifetime than placebo.
Peptide
Semaglutide
Outcome
DecreaseLifetime cost savings, full population
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
Cost saving
6068 DKK
full population
Source sentences
Summary
Semaglutide was associated with long-term, per-person cost savings of DKK 6,068 in the full population and DKK 9,212 in those not receiving SGLT-2 inhibitors at baseline, leading to semaglutide being a dominant treatment compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202705
06Computer modelIn silicoOther
In a model of adults with type 2 diabetes and chronic kidney disease in Denmark not receiving SGLT-2 inhibitors, semaglutide was projected to save DKK 9,212 per person versus placebo.
In plain wordsIn a computer model of Danish adults with diabetes and kidney disease not on SGLT-2 drugs, semaglutide was projected to cost less than placebo.
Peptide
Semaglutide
Outcome
DecreaseLifetime cost savings, patients not on SGLT-2 inhibitors
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
Cost saving
9212 DKK
no SGLT-2 inhibitors at baseline
Source sentences
Summary
Semaglutide was associated with long-term, per-person cost savings of DKK 6,068 in the full population and DKK 9,212 in those not receiving SGLT-2 inhibitors at baseline, leading to semaglutide being a dominant treatment compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202706
07Computer modelIn silicoOther
In a model of adults with type 2 diabetes and chronic kidney disease in Denmark receiving SGLT-2 inhibitors, semaglutide was cost-effective versus placebo, with an ICER of DKK 19,167 per QALY gained.
In plain wordsIn a computer model of Danish adults with diabetes and kidney disease on SGLT-2 drugs, semaglutide was judged cost-effective compared with placebo.
Peptide
Semaglutide
Outcome
Not applicableICER, patients on SGLT-2 inhibitors
Study
n: not reported in source
PRIME T2D Model
Comparator
Placebo
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
ICER
19,167 DKK per QALY
SGLT-2 inhibitors at baseline
Source sentences
Summary
In patients receiving SGLT-2 inhibitors at baseline, semaglutide was cost-effective with an ICER of DKK 19,167 per QALY gained.
1 context sentence(design, population, supporting numbers)
Summary · context
Life expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model.
Report a problemFND-4142202707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Novo Nordisk A/Sn = 3,53317 Jun 2019 to 9 Jan 2024

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 20 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.

Summary

Results from this study7

Registered trials1

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Version history

Subjects

Publication types

MeSH terms

Keywords